Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

@article{Maxwell2008MismatchRD,
  title={Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.},
  author={Jill A Maxwell and Stewart P. Johnson and Roger E McLendon and David W Lister and Krystle S Horne and Ahmed Rasheed and Jennifer A. Quinn and Francis R Ali-Osman and Allan H. Friedman and Paul L. Modrich and Darell D Bigner and Henry S. Friedman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 15},
  pages={4859-68}
}
PURPOSE A major mechanism of resistance to methylating agents, including temozolomide, is the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT). Preclinical data indicates that defective DNA mismatch repair (MMR) results in tolerance to temozolomide regardless of AGT activity. The purpose of this study was to determine the role of MMR deficiency in mediating resistance in samples from patients with both newly diagnosed malignant gliomas and those who have failed temozolomide… CONTINUE READING